المؤلفون: Recio, Fernando, Scalise, Carly Bess, Loar, Paul, Lumish, Melissa, Berman, Tara, Peddada, Abhinand, Kalashnikova, Ekaterina, Rivero-Hinojosa, Samuel, Beisch, Tricia, Nicosia, Brittany, Farmer, Tiffany, Dutta, Punashi, Malhotra, Meenakshi, ElNaggar, Adam C., Liu, Minetta C., Vaccarello, Luis, Holloway, Robert W.

المصدر: Gynecologic Oncology ; volume 182, page 63-69 ; ISSN 0090-8258

مصطلحات موضوعية: Obstetrics and Gynecology, Oncology

الإتاحة: https://doi.org/10.1016/j.ygyno.2023.12.025Test
https://api.elsevier.com/content/article/PII:S0090825823016311?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0090825823016311?httpAccept=text/plainTest

المؤلفون: Kalashnikova, Ekaterina, Aushev, Vasily N., Malashevich, Allyson Koyen, Tin, Antony, Krinshpun, Shifra, Salari, Raheleh, Scalise, Carly Bess, Ram, Rosalyn, Malhotra, Meenakshi, Ravi, Harini, Sethi, Himanshu, Sanchez, Stephanie, Hagelstrom, Robert Tanner, Brevnov, Maxim, Rabinowitz, Matthew, Moshkevich, Solomon, Zimmermann, Bernhard G., Liu, Minetta C., Aleshin, Alexey

المصدر: Molecular Oncology ; ISSN 1574-7891 1878-0261

الوصف: Several studies have demonstrated the prognostic value of circulating tumor DNA (ctDNA); however, the correlation of mean tumor molecules (MTM)/ml of plasma and mean variant allele frequency (mVAF; %) with clinical parameters is yet to be understood. In this study, we analyzed ctDNA data in a pan‐cancer cohort of 23 543 patients who had ctDNA testing performed using a personalized, tumor‐informed assay (Signatera™, mPCR‐NGS assay). For ctDNA‐positive patients, the correlation between MTM/ml and mVAF was examined. Two subanalyses were performed: (a) to establish the association of ctDNA with tumor volume and (b) to assess the correlation between ctDNA dynamics and patient outcomes. On a global cohort, a positive correlation between MTM/ml and mVAF was observed. Among 18 426 patients with longitudinal ctDNA measurements, 13.3% had discordant trajectories between MTM/ml and mVAF at subsequent time points. In metastatic patients receiving immunotherapy ( N = 51), changes in ctDNA levels expressed both in MTM/ml and mVAF showed a statistically significant association with progression‐free survival; however, the correlation with MTM/ml was numerically stronger.

الإتاحة: https://doi.org/10.1002/1878-0261.13557Test

المؤلفون: Lebow, Emily S., Shaverdian, Narek, Eichholz, Jordan E., Kratochvil, Leah B., McCune, Megan, Murciano-Goroff, Yonina R., Jee, Justin, Eng, Juliana, Chaft, Jamie E., Kris, Mark G., Kalashnikova, Ekaterina, Feeney, Jordan, Scalise, Carly Bess, Sudhaman, Sumedha, Palsuledesai, Charuta C., Malhotra, Meenakshi, Krainock, Michael, Sethi, Himanshu, Aleshin, Alexey, Liu, Minetta C., Shepherd, Annemarie F., Wu, Abraham J., Simone, Charles B., Gelblum, Daphna Y., Johnson, Kaylie A., Rudin, Charles M., Gomez, Daniel R., Razavi, Pedram, Reis-Filho, Jorge S., Isbell, James M., Li, Bob T., Rimner, Andreas

المصدر: Frontiers in Oncology ; volume 13 ; ISSN 2234-943X

مصطلحات موضوعية: Cancer Research, Oncology

الوصف: Background Sensitive and reliable biomarkers for early detection of recurrence are needed to improve post-definitive radiation risk stratification, disease management, and outcomes for patients with unresectable early-stage or locally advanced non-small cell lung cancer (NSCLC) who are treated with definitive radiation therapy (RT). This prospective, multistate single-center, cohort study investigated the association of circulating tumor DNA (ctDNA) status with recurrence in patients with unresectable stage I-III NSCLC who underwent definitive RT. Methods A total of 70 serial plasma samples from 17 NSCLC patients were collected before, during, and after treatment. A personalized, tumor-informed ctDNA assay was used to track a set of up to 16 somatic, single nucleotide variants in the associated patient’s plasma samples. Results Pre-treatment ctDNA detection rate was 82% (14/17) and varied based on histology and stage. ctDNA was detected in 35% (6/17) of patients at the first post-RT timepoint (median of 1.66 months following the completion of RT), all of whom subsequently developed clinical progression. At this first post-RT time point, patients with ctDNA-positivity had significantly worse progression-free survival (PFS) [hazard ratio (HR): 24.2, p=0.004], and ctDNA-positivity was the only significant prognostic factor associated with PFS (HR: 13.4, p=0.02) in a multivariate analysis. All patients who developed clinical recurrence had detectable ctDNA with an average lead time over radiographic progression of 5.4 months, and post-RT ctDNA positivity was significantly associated with poor PFS (p<0.0001). Conclusion Personalized, longitudinal ctDNA monitoring can detect recurrence early in patients with unresectable NSCLC patients undergoing curative radiation and potentially risk-stratify patients who might benefit most from treatment intensification.

الإتاحة: https://doi.org/10.3389/fonc.2023.1253629Test

المؤلفون: Monavarian, Mehri, Elhaw, Amal Taher, Tang, Priscilla W., Javed, Zaineb, Shonibare, Zainab, Scalise, Carly Bess, Arend, Rebecca, Jolly, Mohit Kumar, Sewell- Loftin, Mary Kathryn, Hempel, Nadine, Mythreye, Karthikeyan

المساهمون: National Institutes of Health

المصدر: Seminars in Cancer Biology ; volume 86, page 709-719 ; ISSN 1044-579X

مصطلحات موضوعية: Cancer Research

الإتاحة: https://doi.org/10.1016/j.semcancer.2022.03.004Test
https://api.elsevier.com/content/article/PII:S1044579X22000608?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1044579X22000608?httpAccept=text/plainTest

المؤلفون: Pham, Melissa, Scalise, Carly Bess, Kalashnikova, Ekaterina, Dutta, Punashi, Chen, Xi, Narcisse, Subrina, Rangel, Kelly, Urbauer, Diana, Elnaggar, Adam, Westin, Shannon, Jazaeri, Amir, Lu, Karen, Soliman, Pamela

المصدر: ePoster Viewing

الإتاحة: https://doi.org/10.1136/ijgc-2023-igcs.251Test

المؤلفون: Recio, Fernando, Orr, Brian, Castaneda, Kayla, Saldivar, Jose, Chae, Young Kwang, Sindhu, Hemant, Diaz-Arrastia, Concepcion, Grzankowski, Kassondra, Azzi, Georges, Scalise, Carly Bess, Kalashnikova, Ekaterina, Nicosia, Brittany, Beisch, Tricia, Palsuledesai, Charuta, ElNaggar, Adam, Liu, Minetta, Holloway, Robert

المصدر: Gynecologic Oncology ; volume 176, page S313-S314 ; ISSN 0090-8258

مصطلحات موضوعية: Obstetrics and Gynecology, Oncology

الإتاحة: https://doi.org/10.1016/j.ygyno.2023.06.415Test
https://api.elsevier.com/content/article/PII:S0090825823012155?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0090825823012155?httpAccept=text/plainTest

المؤلفون: Recio, Fernando, Vaccarello, Luis, Loar, Paul, Peddada, Abhinand, Scalise, Carly Bess, Kalashnikova, Ekaterina, Beisch, Tricia, Nicosia, Brittany, Farmer, Tiffany, Dutta, Punashi, ElNaggar, Adam, Liu, Minetta, Holloway, Robert

المصدر: Gynecologic Oncology ; volume 176, page S8-S9 ; ISSN 0090-8258

مصطلحات موضوعية: Obstetrics and Gynecology, Oncology

الإتاحة: https://doi.org/10.1016/j.ygyno.2023.06.476Test
https://api.elsevier.com/content/article/PII:S0090825823012763?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0090825823012763?httpAccept=text/plainTest

المؤلفون: Castaneda, Kayla, Saldivar, Jose Salvador, Chae, Young Kwang, Sindhu, Hemant, Diaz-Arrastia, Concepcion, Grzankowski, Kassondra, Azzi, Georges, Scalise, Carly Bess, Kalashnikova, Ekaterina, Nicosia, Brittany, Tekula, Shilpa, Aleshin, Alexey, ElNaggar, Adam C

المصدر: Translational research/biomarkers

الإتاحة: https://doi.org/10.1136/ijgc-2022-esgo.879Test

المؤلفون: Scalise, Matthew, Foxall, McKenzie, Thigpen, Haley, Scalise, Carly Bess, Arend, Rebecca

المصدر: Gynecologic Oncology ; volume 162, page S287 ; ISSN 0090-8258

مصطلحات موضوعية: Obstetrics and Gynecology, Oncology

الإتاحة: https://doi.org/10.1016/s0090-8258Test(21)01196-3
https://api.elsevier.com/content/article/PII:S0090825821011963?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0090825821011963?httpAccept=text/plainTest

المؤلفون: Dholakia, Jhalak, Wall, Jaclyn, Scalise, Carly Bess, Katre, Ashwini, Arend, Rebecca

المصدر: Gynecologic Oncology ; volume 162, page S12 ; ISSN 0090-8258

مصطلحات موضوعية: Obstetrics and Gynecology, Oncology

الإتاحة: https://doi.org/10.1016/s0090-8258Test(21)00670-3
https://api.elsevier.com/content/article/PII:S0090825821006703?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0090825821006703?httpAccept=text/plainTest